Arix Bioscience (ARIX)

 

ARIX Share PerformanceMore

52 week high218.00 17/02/17
52 week low167.50 16/08/17
52 week change 0.00 (0.00%)
4 week volume362,485 16/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Arix leads $30m financing for Atox Bio

Arix Bioscience has led an oversubscribed $30 million series F financing round for Atox Bio. Atox Bio is a late stage clinica...

Arix Bioscience leads $30m financing for Atox Bio

RNS Number: 2209Y Arix Bioscience Plc 04 December 2017 Arix Bioscience leads $30 million financing for Atox Bio Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical development in necrotising soft tissue infections Arix achieves target of 12 Group Businesses by the end of 2017, suc...

Arix Bioscience non-exec to step down

Arix Bioscience non-executive director Sir John Banham is retiring from the board. The company said: 'Sir John, who is 76...

Sir John Banham retires from Board of Directors

RNS Number: 1565W Arix Bioscience Plc 10 November 2017 Sir John Banham retires from Board of Directors of Arix Bioscience plc LONDON, 10 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces that Sir John Banham is retiring fro...

Arix to present at two IR conferences

RNS Number: 1740V Arix Bioscience Plc 01 November 2017 Arix Bioscience to present at two investor conferences in November LONDON, 1 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, will present at two investor conferences in November: Stifel 2017 Healthcare Co...

Arix notes Harpoon AbbVie IO collaboration

RNS Number: 9605T Arix Bioscience Plc 18 October 2017 Arix Bioscience notes Harpoon Therapeutics' immuno-oncology collaboration with AbbVie LONDON, 18 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note that Harpoon Therapeutics ("Harpoon"), an...

Arix Bioscience strengthens its board

Arix Bioscience has appointed Giles Kerr as a non-executive director and chairman of the board's audit committee. Kerr h...

Director Declaration

RNS Number: 7531T BTG PLC 17 October 2017 BTG plc 17 October 2017 Director Declaration BTG plc announces today that Mr Giles Kerr, Non-executive Director of the Company, has been appointed as a Non-executive Director and Audit Committee Chair of Arix Bioscience plc with effect from 17 October 2017. This announcement is made pursuant to Listing Rule...

Fundamental DataMore

EPS-0.36
Dividend yield0 %

Latest discussion posts More

  • Re: welcome

    Blimey, what's going on? Some negative news out there? IPO oversubscribed and some major holdings - it should be heading the other way. JC
    5-Apr-2017
    JohnyCash
  • Re: welcome

    Been a bit of a dog so far
    5-Apr-2017
    livadia22
  • Re: welcome

    I could not make sense as to what this company is about. Is it similar to Shire which funds R&D through other Biotechs, but it does not have its owns labs?
    6-Mar-2017
    raptor66

Users' HoldingsMore

Users who hold Arix Bioscience also hold..

Codes & Symbols

ISINGB00BD045071
SymbolsARIX, LSE:ARIX, ARIX.L, ARIX:LN, LON:ARIX, XLON:ARIX

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account